Overexpression of miR-378 is frequent and may affect treatment outcomes in patients with acute myeloid leukemia

Qian, Jun; Jiang, Lin; Qian, Wei; Ma, Ji‐chun; Shen, Qian; Li, Yun; Yang, Jing; Li, Jianyong; Wang, Cui-zhu; Chai, Hai-yan; Chen, Xing‐Xing; Deng, Zhaoqun

doi:10.1016/j.leukres.2013.03.014

Cited by 40 publications

(41 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32 In particular, overexpression of the miR-17~92a cluster has been widely studied, and has been implicated in both benign and malignant lymphoproliferative diseases, 33 whereas the functions of the miRNAs in the miR-106a~363 cluster, which share numerous seed sequences with the 17~92a cluster miRNAs, are less well explored. 34 Overexpression of miR-378d has been associated with poor prognosis in acute myeloid leukemia, 35 and with brain metastasis in non-small cell lung cancer, 36 but has to our knowledge not been implicated in lymphoid malignancies.…”

Section: Discussionmentioning

confidence: 99%

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

Husby¹,

Ralfkiær

Garde

et al. 2015

Blood

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

Husby¹,

Ralfkiær

Garde

et al. 2015

Blood

View full text Add to dashboard Cite

show abstract

“…All samples determined positive by high-resolution melting analysis (HRMA) were further confirmed by direct DNA sequencing. FLT3/ ITD and CCAAT enhancer binding protein alpha (C/EBPA) mutations were detected using DNA sequencing (29,30).…”

Section: Gene Mutation Detectionmentioning

confidence: 99%

ReducedmiR-215expression predicts poor prognosis in patients with acute myeloid leukemia

Wang

Zhang

Yang

et al. 2016

Jpn. J. Clin. Oncol.

Self Cite

View full text Add to dashboard Cite

Objective: Abnormal expression of microRNA-215 has been identified in a variety of solid cancers. However, little is known about the expression pattern of microRNA-215 in acute myeloid leukemia. This study was to investigate the status of microRNA-215 expression and further analyze its clinical significance in acute myeloid leukemia. Methods: Real-time quantitative polymerase chain reaction assay was performed to evaluate the expression level of microRNA-215 in 113 patients with acute myeloid leukemia. Besides, the relationship between microRNA-215 levels and clinical and pathological factors was explored. Results: Compared with the healthy individuals, microRNA-215 expression in acute myeloid leukemia patients was significantly down-regulated (P = 0.001). MicroRNA-215 low-expressed patients had higher white blood cells than microRNA-215 high-expressed patients (P = 0.014). The incidence of FLT3/ITD mutation in the patients with low microRNA-215 expression was significantly higher than those with high microRNA-215 expression (P = 0.025). MicroRNA-215 low-expressed patients had significantly shorter overall survival than microRNA-215 high-expressed patients in both non-M3 acute myeloid leukemia patients and cytogenetically normal patients (P = 0.017 and P = 0.044, respectively). Meanwhile, multivariate analysis confirmed the adverse prognostic value of microRNA-215 expression in acute myeloid leukemia patients with non-M3 subtypes. Conclusions: Our study demonstrates that reduced microRNA-215 expression is a common event and is associated with poor clinical outcome in acute myeloid leukemia.

show abstract

“…Studies have shown that upregulation of miR-378 in AML is a common event and may have a detrimental effect on the prognosis of AML [22]. The results of this study show that FUS1 expression in AML is decreased, indicating that FUS1 has an important inhibitory effect in AML.…”

Section: Discussionmentioning

confidence: 51%

“…Studies have confirmed that miR-378 can enhance cell survival and promote tumor growth and angiogenesis [20, 21]. miR-378 was found to be upregulated in AML and had an effect on the prognosis [22]. Therefore, we studied the association between the expression of FUS1 and miR-378 in 53 newly diagnosed AML patients.…”

Section: Resultsmentioning

confidence: 99%

Low Expression of <b><i>FUS1</i></b> Is Negatively Correlated with miR-378 and May Predict Adverse Prognoses in Acute Myeloid Leukemia

et al. 2018

Self Cite

View full text Add to dashboard Cite

FUS1 is a tumor suppressor gene that has been found to be frequently lost in a variety of solid tumors. In this study, we aimed to investigate the expression status of the FUS1 gene in acute myeloid leukemia (AML), as well as its clinical significance. We further explored the correlation between the expression of FUS1 and miR-378 in AML. We detected expression of the FUS1 transcript in bone marrow mononuclear cells from 23 controls and 158 newly diagnosed AML patients by real-time quantitative polymerase chain reaction. Downregulated FUS1 expression was found in 139 out of 158 (87.97%) AML cases; this rate was significantly lower than that in all 23 controls (p = 0.012). Receiver operating characteristic curve analysis revealed that the FUS1 transcript level could discriminate AML patients from controls effectively (area under the ROC curve = 0.663). Kaplan-Meier analysis demonstrated that non-M3-AML patients with a low FUS1 expression had a shorter overall survival (p = 0.049) and leukemia-free survival (p = 0.051) than those with a high FUS1 expression. Furthermore, we studied the correlation between the expression of FUS1 and miR-378 in 53 newly diagnosed AML patients. We found that the correlation coefficient was –0.346, which showed that FUS1 and miR-378 were negatively correlated in AML patients (p = 0.011). These results indicate that the low expression of FUS1 is a common molecular event in AML.

show abstract

Overexpression of miR-378 is frequent and may affect treatment outcomes in patients with acute myeloid leukemia

Cited by 40 publications

References 36 publications

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

ReducedmiR-215expression predicts poor prognosis in patients with acute myeloid leukemia

Low Expression of <b><i>FUS1</i></b> Is Negatively Correlated with miR-378 and May Predict Adverse Prognoses in Acute Myeloid Leukemia

Contact Info

Product

Resources

About